Oramed Patent Allowed in the U.S. for Oral Exenatide
Oramed Pharmaceuticals Inc. (ORMP)
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm
Check Earnings Report
US:NASDAQ Investor Relations:
oramed.com/investors
Company Research
Source: PR Newswire
NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been allowed by the United States Patent and Trademark Office. Nadav Kidron, CEO of Oramed, stated, "This is another important patent in Oramed's patent portfolio that protects a key aspect of our breakthrough technology with regards to oral Exenatide. This patent allowance comes as we are completing our phase I study with our ORMD-0901 oral exenatide capsule under an IND in the U.S."About Oramed PharmaceuticalsOramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of res
Show less
Read more
Impact Snapshot
Event Time:
ORMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORMP alerts
High impacting Oramed Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ORMP
News
- PhaseV to Present at Upcoming Clinical Trial Events and Scientific Meetings, Highlighting the Value of Machine Learning in Drug Development [Yahoo! Finance]Yahoo! Finance
- Scilex Holding repays the remaining balance of convertible debentures [Seeking Alpha]Seeking Alpha
- Oramed Letter to Shareholders [Yahoo! Finance]Yahoo! Finance
- Oramed Letter to ShareholdersPR Newswire
ORMP
Earnings
- 11/9/23 - Beat
ORMP
Sec Filings
- 4/18/24 - Form 4
- 4/2/24 - Form 3
- 3/22/24 - Form SC
- ORMP's page on the SEC website